{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:55:16Z","timestamp":1793044516849,"version":"4.5.0"},"reference-count":27,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"Q2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Over the past 30 years, the treatment landscape for multiple sclerosis (MS) has become increasingly complex. All MS disease-modifying therapies (DMTs) and several symptomatic medications are designated specialty medications, and their financial coverage is subject to complicated insurance processes and a wide array of patient support programs. Many patients receiving MS DMTs need ongoing monitoring or enrollment in a Risk Evaluation and Mitigation Strategy program. Integrated pharmacy services can facilitate financial, technical, and educational aspects of providing specialty medications. Although pharmacy services are often part of the care team for patients with complex chronic medical conditions, MS clinics may not have the benefit of full pharmacy services. We present 4 models of MS health care delivery and discuss how integrating pharmacy services into an MS multidisciplinary team can potentially increase the efficiency and quality of health care delivery. Clinical pharmacists, working with other providers, can optimize and accelerate access to medications requiring prior authorization, improve patient outcomes by promoting medication adherence and persistence, enhance safety by monitoring laboratory findings and potential drug-drug interactions, and minimize clinical workflow burden by improving process efficiency, which may be cost-effective for the MS health care delivery system.<\/jats:p>\n               <\/jats:sec>","DOI":"10.7224\/1537-2073.2024-019","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:47:38Z","timestamp":1745236058000},"page":"117-124","source":"Crossref","is-referenced-by-count":1,"title":["Integrating Clinical Pharmacy Services Into Comprehensive Multiple Sclerosis Care Teams: A Narrative Review of 4 Models"],"prefix":"10.7224","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7886-9756","authenticated-orcid":false,"given":"Nina","family":"Bozinov","sequence":"first","affiliation":[{"name":"From Kootenai Clinic Neurology, Coeur d'Alene, ID"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Ramsrud","sequence":"additional","affiliation":[{"name":"From Kootenai Clinic Neurology, Coeur d'Alene, ID"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenelle H.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Duke Neuroscience Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Merrill","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis and Neuroinflammation Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Rajkovic","sequence":"additional","affiliation":[{"name":"UCHealth Outpatient Neurology Clinics, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita V.","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado, Aurora, CO, USA"},{"name":"Department of Neurology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"11","key":"2025042111473214800_b1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2146\/ajhp150723","article-title":"Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems","volume":"73","author":"Habibi","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"2025042111473214800_b2","unstructured":"Ambizas\n              EM\n            \n          . Multiple sclerosis. U.S. Pharmacist. March15, 2022. Accessed January 6, 2023. https:\/\/www.uspharmacist.com\/article\/multiple1-sclerosis"},{"issue":"2","key":"2025042111473214800_b3","first-page":"S28","article-title":"Managed care aspects of managing multiple sclerosis","volume":"19","author":"Mathis","year":"2013","journal-title":"Am J Manag Care"},{"key":"2025042111473214800_b4","doi-asserted-by":"crossref","first-page":"1063904","DOI":"10.3389\/fneur.2022.1063904","article-title":"Shared decision-making in patients with multiple sclerosis","volume":"13","author":"Ubbink","year":"2022","journal-title":"Front Neurol"},{"issue":"1","key":"2025042111473214800_b5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7224\/1537-2073.2019-032","article-title":"Incorporation and impact of a clinical pharmacist in a hospital-based neurology clinic treating patients with multiple sclerosis","volume":"23","author":"May","year":"2021","journal-title":"Int J MS Care"},{"issue":"6","key":"2025042111473214800_b6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.7224\/1537-2073.2017-070","article-title":"Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis","volume":"20","author":"Ben-Zacharia","year":"2018","journal-title":"Int J MS Care"},{"issue":"4","key":"2025042111473214800_b7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/pharmacy9040187","article-title":"Patient satisfaction with pharmacist-provided health-related services in a primary care clinic","volume":"9","author":"Jordan","year":"2021","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"2025042111473214800_b8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0897190018824821","article-title":"Adherence to disease-modifying therapies at a multiple sclerosis clinic: the role of the specialty pharmacist","volume":"33","author":"Banks","year":"2020","journal-title":"J Pharm Pract"},{"issue":"1","key":"2025042111473214800_b9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.msard.2014.09.214","article-title":"Therapy optimization in multiple sclerosis: a cohort study of therapy adherence and risk of relapse","volume":"4","author":"Cohen","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2025042111473214800_b10","first-page":"139","article-title":"Improving patient self-management of multiple sclerosis through a disease therapy management program","volume":"16","author":"Stockl","year":"2010","journal-title":"Am J Manag Care"},{"issue":"6","key":"2025042111473214800_b11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2146\/ajhp130495","article-title":"Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis","volume":"71","author":"Hanson","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"2025042111473214800_b12","first-page":"S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2025042111473214800_b13","unstructured":"Ungerleider\n              DL\n            \n          . Multiple sclerosis, DMTs, and the role of specialty pharmacists. MedPage Today. August23, 2022Accessed January 6, 2023. https:\/\/www.medpagetoday.com\/resource-centers\/advances-in-multiple-sclerosis\/multiple-sclerosis-dmts-and-role-specialty-pharmacists\/4043"},{"key":"2025042111473214800_b14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PPA.S8230","article-title":"Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence","volume":"4","author":"Patti","year":"2010","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2025042111473214800_b15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7224\/1537-2073.2011-038","article-title":"Facilitating medication adherence in patients with multiple sclerosis","volume":"15","author":"Remington","year":"2013","journal-title":"Int J MS Care"},{"issue":"1","key":"2025042111473214800_b16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/13524585221122207","article-title":"Polypharmacy and multiple sclerosis: a population-based study","volume":"29","author":"Chertcoff","year":"2022","journal-title":"Mult Scler"},{"issue":"3","key":"2025042111473214800_b17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/pharmaceutics14030592","article-title":"Prevalence and severity of potential drug-drug interactions in patients with multiple sclerosis with and without polypharmacy","volume":"14","author":"Bachmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025042111473214800_b18","doi-asserted-by":"crossref","first-page":"1756286420969501","DOI":"10.1177\/1756286420969501","article-title":"The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis","volume":"13","author":"Frahm","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"2025042111473214800_b19","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.25011\/cim.v42i1.32383","article-title":"Comorbidity in multiple sclerosis: past, present and future","volume":"42","author":"Marrie","year":"2019","journal-title":"Clin Invest Med"},{"issue":"1","key":"2025042111473214800_b20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/2772432817666220412110720","article-title":"Safety and monitoring of the treatment with disease-modifying therapies (DMTs) for multiple sclerosis (MS)","volume":"18","author":"Stamatellos","year":"2023","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"4","key":"2025042111473214800_b21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/pharmacy8040239","article-title":"Implementation of smart infusion pumps: a scoping review and case study discussion of the evidence of the role of the pharmacist","volume":"8","author":"Shah","year":"2020","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"2025042111473214800_b22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40258-022-00733-0","article-title":"ENTIMOS: a discrete event simulation model for maximising efficiency of infusion suites in centres treating multiple sclerosis patients","volume":"20","author":"Lacinova","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"2025042111473214800_b23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"2025042111473214800_b24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"2025042111473214800_b25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"9856","key":"2025042111473214800_b26","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"2025042111473214800_b27","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/27\/Q2\/117\/3509175\/i1537-2073-27-117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/27\/Q2\/117\/3509175\/i1537-2073-27-117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:13:21Z","timestamp":1752786801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/integrating-clinical-pharmacy-into-multiple-sclerosis-care-teams"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":27,"journal-issue":{"issue":"Q2","published-online":{"date-parts":[[2025,4,21]]},"published-print":{"date-parts":[[2025,4,21]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2024-019","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}